Long-term effect of first-line injectable multiple sclerosis treatments: Input of a time-dependent propensity score

Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1680-1688. doi: 10.1002/pds.5154. Epub 2020 Nov 11.

Abstract

Purpose: The long-term effect of beta-interferon and glatiramer acetate on multiple sclerosis (MS) disability progression has resulted in controversial results, probably due to a lack of appropriate control of biases as raised in observational studies. In particular, the time of the therapeutic decision is difficult to define when the controls are not treated.

Methods: This retrospective observational study was based on a series of patients from the MS expert center in Rennes, France. We used a time-dependent propensity score defined as the linear predictor of a Cox model estimating the hazard of being treated at each time from MS onset. The matching procedure resulted in two groups: patients matched as treated and as not yet treated. The restricted mean times (RMST) to reach a moderate level of disability or worsening of the disability were compared between the two groups in an intention-to-treat analysis.

Results: Of the 2383 patients included in the study, 556 were matched as treated. The matching procedure provided a good balance of both the time-fixed and the time-dependent covariates. A slight difference was observed for the time to reach a moderate level of disability, in favor of the "not yet treated" group (difference in the RMST: -0.62 [-0.91; -0.33]) while no difference was found in terms of worsening of the disability (-0.03 [-0.24; 0.33]).

Conclusion: This unexpected result is probably due to unmeasured confounders. However, this time-dependent PS warrants consideration in long-term effectiveness studies.

Keywords: disability progression; effectiveness; multiple sclerosis; observational study; pharmacoepidemiology; propensity score.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Glatiramer Acetate
  • Humans
  • Interferon-beta
  • Multiple Sclerosis* / drug therapy
  • Propensity Score
  • Retrospective Studies

Substances

  • Glatiramer Acetate
  • Interferon-beta